Does the combination of optimal substitutions at the C 2-, N 5- and N 8-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A 3 adenosine receptors?

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 20, 2011, Pages 6120-6134

  Cheong, Siew Lee ^a   Dolzhenko, Anton V ^a   Paoletta, Silvia ^b   Lee, Evelyn Pei Rong ^a   Kachler, Sonja ^c   Federico, Stephanie ^d   Klotz, Karl Norbert ^c   Dolzhenko, Anna V ^a   Spalluto, Giampiero ^d   Moro, Stefano ^b   Pastorin, Giorgia ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF TRIESTE   (Italy)

Author keywords

2 Phenyl pyrazolo triazolo pyrimidines; Affinity; Human A 3 adenosine receptor antagonists; Selectivity; Structure affinity relationship

Indexed keywords

2 (4 BIPHENYL) 8 METHYLPYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDIN 5 AMINE; 2 (4 BIPHENYL) 8 METHYLPYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 2 (4 BROMOPHENYL) 8 METHYLPYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 2 (4 CHLOROPHENYL) 8 METHYLPYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5(3) (3 AMINO 2 METHYLPYRAZOL 4 YL) 3(5) (4 BIPHENYL) 1,2,4 TRIAZOLE; 5(3) (3 AMINO 2 METHYLPYRAZOL 4 YL) 3(5) (4 BROMOPHENYL) [1,2,4] 1H TRIAZOLE; 5(3) (3 AMINO 2 METHYLPYRAZOL 4 YL) 3(5) (4 CHLOROPHENYL) [1,2,4] 1H TRIAZOLE; 5(3) (3 AMINO 2 METHYLPYRAZOL 4 YL) 3(5) (4 TRIFLUOROMETHYLPHENYL) 1,2,4 TRIAZOLE; 8 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDIN 5 AMINE; 8 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; A3 ADENOSINE RECEPTOR; ADENOSINE RECEPTOR; N (4 FLUOROPHENYL) N' 8 METHYL 2 (4 TRIFLUOROMETHYLPHENYL)PYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL UREA; N (4 METHOXYPHENYL) N' 8 METHYL 2 (4 TRIFLUOROMETHYLPHENYL)PYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL N' (4 METHOXYPHENYL)UREA; N [2 (4 BIPHENYL) 8 METHYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL] N' (4 FLUOROPHENYL)UREA; N [2 (4 BIPHENYL) 8 METHYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL] N' PHENYLUREA; N [2 (4 BROMOPHENYL) 8 METHYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL] N' (4 METHOXYPHENYL)UREA; N [2 (4 BROMOPHENYL) 8 METHYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL] N' PHENYLUREA; N [2 (4 CHLOROPHENYL) 8 METHYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL] N' (4 FLUOROPHENYL)UREA; N [2 (4 CHLOROPHENYL) 8 METHYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL] N' (4 METHOXYPHENYL)UREA; N [2 (4 CHLOROPHENYL) 8 METHYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL] N' PHENYLUREA; N [2 (4 CHLOROPHENYL) 8 PHENYLETHYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL]BENZAMIDE; N [2 (4 FLUOROPHENYL) 8 PHENYLETHYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL]BENZAMIDE; N [2 (4 FLUOROPHENYL) 8 PHENYLETHYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL]PHENYLACETAMIDE; N [2 (4 METHOXYPHENYL) 8 PHENYLETHYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL]BENZAMIDE; N [2 (PHENYL) 8 PHENYLETHYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL]PHENYLACETAMIDE; N [8 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) PYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 5 YL] N' PHENYLUREA; PYRAZOLOTRIAZOLOPYRIMIDINE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CHEMICAL MODIFICATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; MODULATION; MOLECULAR MODEL; NONHUMAN;

ANIMALS; CHO CELLS; CRICETINAE; HUMANS; MODELS, MOLECULAR; PYRAZOLES; PYRIDINES; RECEPTOR, ADENOSINE A3; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 80053237248     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.08.026     Document Type: Article

References (35)

1. K.A. Jacobson, and Z.G. Gao Nat. Rev. Drug Disc. 5 2006 247
2. S. Moro, Z.G. Gao, K.A. Jacobson, and G. Spalluto Med. Res. Rev. 26 2006 131
3. K.A. Jacobson Trends Pharmacol. Sci. 19 1998 184
4. S. Merighi, P. Mirandola, K. Varani, S. Gessi, E. Leung, P.G. Baraldi, M.A. Tabrizi, and P.A. Borea Pharmacol. Ther. 100 2003 31
5. C.E. Müller, and K.A. Jacobson Biochim. Biophys. Acta 1808 2011 1290
6. B.B. Fredholm, A.P. IJzerman, K.A. Jacobson, J. Linden, and C.E. Müller Pharmacol. Rev. 63 2011 1
7. P.G. Baraldi, B. Cacciari, P.A. Borea, K. Varani, G. Pastorin, T. Da Ros, M.A. Tabrizi, F. Fruttarolo, and G. Spalluto Curr. Pharm. Des. 8 2002 2299
8. P.G. Baraldi, B. Cacciari, R. Romagnoli, K.N. Klotz, G. Spalluto, K. Varani, S. Gessi, S. Merighi, and P.A. Borea Drug Dev. Res. 53 2001 225
9. A. Maconi, G. Pastorin, T. Da Ros, G. Spalluto, Z.G. Gao, K.A. Jacobson, P.G. Baraldi, B. Cacciari, K. Varani, and P.A. Borea J. Med. Chem. 45 2002 3579
10. P.G. Baraldi, B. Cacciari, S. Moro, G. Spalluto, G. Pastorin, T. Da Ros, K.-N. Klotz, K. Varani, S. Gessi, and P.A. Borea J. Med. Chem. 45 2002 770
11. S.L. Cheong, A. Dolzhenko, S. Kachler, S. Paoletta, S. Federico, B. Cacciari, Ant. Dolzhenko, K.N. Klotz, S. Moro, G. Spalluto, and G. Pastorin J. Med. Chem. 53 2010 3361
12. F. Gatta, M.R. Del Giudice, A. Borioni, P.A. Borea, S. Dionisotti, and E. Ongini Eur. J. Med. Chem. 28 1993 569
13. P. Schmidt, K. Eichenberger, M. Wilhelm, and J. Druey Helv. Chim. Acta 42 1959 763
14. A.V. Dolzhenko, G. Pastorin, A.V. Dolzhenko, and W.K. Chui Tetrahedron Lett. 50 2009 5617
15. P.G. Baraldi, B. Cacciari, G. Spalluto, X.-D. Ji, M.E. Olah, G. Stiles, S. Dionisotti, C. Zocchi, E. Ongini, and K.A. Jacobson J. Med. Chem. 39 1996 802
16. P.G. Baraldi, B. Cacciari, M.J. Pineda de Las Infantas, R. Romagnoli, G. Spalluto, R. Volpini, S. Costanzi, S. Vittori, G. Cristalli, N. Melman, K.-S. Park, X.-D. Ji, and K.A. Jacobson J. Med. Chem. 41 1998 3174
17. P.G. Baraldi, B. Cacciari, R. Romagnoli, G. Spalluto, S. Moro, K.N. Klotz, E. Leung, K. Varani, S. Gessi, S. Merighi, and P.A. Borea J. Med. Chem. 43 2000 4768
18. P.G. Baraldi, A. Bovero, F. Fruttarolo, R. Romagnoli, M.A. Tabrizi, D. Pretia, K. Varani, P.A. Borea, and A.R. Moorman Bioorg. Med. Chem. 11 2003 4161
19. K.N. Klotz, J. Hessling, J. Hegler, C. Owman, B. Kull, B.B. Fredholm, and M.J. Lohse Naunyn-Schmiedeberg's Arch. Pharmacol. 357 1998 1
20. K.N. Klotz, G. Cristalli, M. Grifantini, S. Vittori, and M.J. Lohse J. Biol. Chem. 260 1985 14659
21. A. De Lean, A.A. Hancock, and R.J. Lefkowitz Mol. Pharmacol. 21 1982 5
22. Y.C. Cheng, and H.R. Prusoff Biochem. Pharmacol. 22 1973 3099
23. O. Lenzi, V. Colotta, D. Catarzi, F. Varano, D. Poli, G. Filacchioni, K. Varani, F. Vincenzi, P.A. Borea, S. Paoletta, E. Morizzo, and S. Moro J. Med. Chem. 52 2009 7640
24. E. Morizzo, S. Federico, G. Spalluto, and S. Moro Curr. Pharm. Des. 15 2009 4069
25. V.P. Jaakola, M.T. Griffith, M.A. Hanson, V. Cherezov, E.Y.T. Chien, J.R. Lane, and A.P. IJzerman Science 322 2008 1211
26. G. Pastorin, T. Da Ros, G. Spalluto, F. Deflorian, S. Moro, B. Cacciari, P.G. Baraldi, S. Gessi, K. Varani, and P.A. Borea J. Med. Chem. 46 2003 4287
27. Z.G. Gao, A. Chen, D. Barak, S.-K. Kim, C.E. Muller, and K.A. Jacobson J. Biol. Chem. 277 2002 19056
28. M.M. Bradford Anal. Biochem. 72 1976 248
29. MOE (Molecular Operating Environment), version 2010.10; software available from Chemical Computing Group Inc. (1010 Sherbrooke Street West, Suite 910, Montreal, Quebec, Canada H3A 2R7); http://www.chemcomp.com.
30. Stewart, J. J. P. MOPAC 7; Fujitsu Limited: Tokyo, Japan, 1993.
31. GOLD suite, version 5.0.1; software available from Cambridge Crystallographic Data Centre Cambridge Crystallographic Data Centre (12 Union Road Cambridge CB2 1EZ UK); http://www.ccdc.cam.ac.uk.
32. J.A. Ballesteros, and H. Weinstein Methods Neurosci. 25 1995 366
33. P. Labute Proteins 75 2009 187
34. T.A. Halgren, R.B. Murphy, R.A. Friesner, H.S. Beard, L.L. Frye, W.T. Pollard, and J.L. Banks J. Med. Chem. 47 2004 1750
35. O. Korb, T. Stützle, and T.E. Exner J. Chem. Inf. Model. 49 2009 84